Tixagevimab + Cilgavimab: First Approval
Susan J Keam
Drugs, doi:10.1007/s40265-022-01731-1
Tixagevimab 150 mg and cilgavimab 150 mg (EVUSHELD TM 150 mg + 150 mg solution for injection; tixagevimab + cilgavimab) is an intramuscular (IM) long-acting monoclonal antibody combination developed by AstraZeneca for the prevention and treatment of COVID-19. In March 2022, tixagevimab + cilgavimab was approved in the UK for pre-exposure prophylaxis of COVID-19 in adults who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and who are unlikely to mount an adequate immune response to COVID-19 vaccination or for whom COVID-19 vaccination is not recommended, and in the EU for the prevention of COVID-19 in adults and adolescents aged ≥ 12 years and weighing ≥40 kg. In December 2021, tixagevimab + cilgavimab was granted Emergency Use Authorization by the US FDA for the pre-exposure prophylaxis of COVID-19 in adults and paediatric individuals (≥ 12 years of age and weighing ≥ 40 kg). This article summarizes the milestones in the development of tixagevimab + cilgavimab leading to this first approval for pre-exposure prophylaxis of COVID-19 in individuals who are not currently infected with SARS-CoV-2. This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s40265-022-01731-1.
Declarations Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content. Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Authors and Affiliations Susan J. Keam 1 1 Springer Nature, Mairangi Bay, Private Bag 65901, Auckland 0754, New Zealand
References
Astrazeneca, AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US
Astrazeneca, Advancing our discovery of novel coronavirus-neutralising antibodies against COVID-19
Astrazeneca, AstraZeneca's Evusheld™ (tixagevimab and cilgavimab) granted provisional approval for pre-exposure prophylaxis (prevention) of COVID-19 in Australia's most at-risk [media release
Astrazeneca, COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials
Astrazeneca, Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population [media release
Astrazeneca, Researching antibodies to target COVID-19
Astrazeneca, Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy
Astrazeneca, Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19
Boggiano, Eisinger, Lerner, Update on and future directions for use of anti-SARS-CoV-2 antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19, Ann Intern Med
Case, Mackin, Errico, Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains, bioRxiv
Dejnirattisai, Huo, Zhou, SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses, Cell
Dejnirattisai, Shaw, Supasa, Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum, Lancet
Dong, Zost, Greaney, Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail, Nat Microbiol
Driouich, Lingas, Luciani, Activity of tixagevimab/ cilgavimab against the Omicron variant of SARS-CoV-2 in a hamster model,
doi:10.21203/rs.3.rs-1399448/v1Holland, Ginde, Paredes, Tixagevimab/cilgavimab for treatment of hospitalised COVID-19 patients: a randomised, double-blind, phase 3 trial, Lancet,
doi:10.2139/ssrn.4087355Levin, Ustianowski, Wit, Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2116620Lonza, Lonza announces agreement to manufacture AstraZeneca's COVID-19 long-acting antibody combination
Loo, Mctamney, Arends, The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans, Sci Transl Med
Montgomery, Hobbs, Padilla, Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial, Lancet Respir Med,
doi:10.1016/S2213-2600(22)00180-1Neerukonda, Vassell, Herrup, Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2, PLoS ONE
Oganesyan, Gao, Shirinian, Structural characterization of a human Fc fragment engineered for lack of effector functions, Acta Crystallogr D Biol Crystallogr
Robbie, Criste, Dall, Wf, A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults, Antimicrob Agents Chemother
Touret, Baronti, Bouzidi, In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate, Sci Rep
Vanblargan, Errico, Halfmann, An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies, Nat Med
Zost, Gilchuk, Case, Potently neutralizing and protective human antibodies against SARS-CoV-2, Nature
{ 'indexed': {'date-parts': [[2024, 8, 9]], 'date-time': '2024-08-09T02:56:46Z', 'timestamp': 1723172206951},
'reference-count': 34,
'publisher': 'Springer Science and Business Media LLC',
'issue': '9',
'license': [ { 'start': { 'date-parts': [[2022, 6, 1]],
'date-time': '2022-06-01T00:00:00Z',
'timestamp': 1654041600000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.springer.com/tdm'},
{ 'start': { 'date-parts': [[2022, 6, 1]],
'date-time': '2022-06-01T00:00:00Z',
'timestamp': 1654041600000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://www.springer.com/tdm'}],
'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2022, 6]]},
'DOI': '10.1007/s40265-022-01731-1',
'type': 'journal-article',
'created': {'date-parts': [[2022, 6, 21]], 'date-time': '2022-06-21T15:03:13Z', 'timestamp': 1655823793000},
'page': '1001-1010',
'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 35,
'title': 'Tixagevimab + Cilgavimab: First Approval',
'prefix': '10.1007',
'volume': '82',
'author': [{'given': 'Susan J.', 'family': 'Keam', 'sequence': 'first', 'affiliation': []}],
'member': '297',
'published-online': {'date-parts': [[2022, 6, 21]]},
'reference': [ { 'key': '1731_CR1',
'unstructured': 'UK Medicines and Healthcare Products Regulatory Agency. Evusheld '
'approved to prevent COVID-19 in people whose immune response is poor '
'[media release]. 17 Mar 2022. https://www.gov.uk/government/news/.'},
{ 'key': '1731_CR2',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2116620',
'author': 'MJ Levin',
'year': '2022',
'unstructured': 'Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 '
'(Tixagevimab-Cilgavimab) for prevention of Covid-19. N Engl J Med. 2022. '
'https://doi.org/10.1056/NEJMoa2116620.',
'journal-title': 'N Engl J Med'},
{ 'key': '1731_CR3',
'unstructured': 'European Medicines Agency. Evusheld: EPAR—assessment report. 2022. '
'https://www.ema.europa.eu/en/medicines/human/EPAR/evusheld. Accessed 4 '
'May 2022.'},
{ 'issue': '1',
'key': '1731_CR4',
'doi-asserted-by': 'publisher',
'first-page': '119',
'DOI': '10.7326/M21-3669',
'volume': '175',
'author': 'CP Boggiano',
'year': '2022',
'unstructured': 'Boggiano CP, Eisinger RWP, Lerner AMMD, et al. Update on and future '
'directions for use of anti-SARS-CoV-2 antibodies: National Institutes of '
'Health Summit on Treatment and Prevention of COVID-19. Ann Intern Med. '
'2022;175(1):119–26.',
'journal-title': 'Ann Intern Med'},
{ 'key': '1731_CR5',
'unstructured': 'AstraZeneca. Advancing our discovery of novel coronavirus-neutralising '
'antibodies against COVID-19 [media release]. 9 June 2020. '
'http://www.astrazeneca.com.'},
{ 'key': '1731_CR6',
'unstructured': 'AstraZeneca. AZD7442 request for Emergency Use Authorization for '
'COVID-19 prophylaxis filed in US [media release]. 5 Oct 2021. '
'http://www.astrazeneca.com.'},
{ 'key': '1731_CR7',
'unstructured': 'AstraZeneca. COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 '
'rapidly advances into Phase III clinical trials [media release]. 9 Oct '
'2020. http://www.astrazeneca.com.'},
{ 'issue': '7821',
'key': '1731_CR8',
'doi-asserted-by': 'publisher',
'first-page': '443',
'DOI': '10.1038/s41586-020-2548-6',
'volume': '584',
'author': 'SJ Zost',
'year': '2020',
'unstructured': 'Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective '
'human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443–9.',
'journal-title': 'Nature'},
{ 'key': '1731_CR9',
'unstructured': 'UK Medicines and Healthcare Products Regulatory Agency. EVUSHELD: UK '
'summary of product characteristics. 2022. '
'https://www.gov.uk/government/publications/regulatory-approval-of-evusheld-tixagevimabcilgavimab/summary-of-product-characteristics-for-evusheld. '
'Accessed 6 May 2022.'},
{ 'key': '1731_CR10',
'unstructured': 'US Food and Drug Administration. EVUSHELD: Emergency Use Authorization '
'(EAU)—full fact sheet for healthcare providers. 2022. '
'https://www.fda.gov/media/154701/download. Accessed 6 May 2022.'},
{ 'key': '1731_CR11',
'unstructured': 'AstraZeneca. Evusheld long-acting antibody combination approved in the '
'EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad '
'population [media release]. 28 Mar 2022. https://www.astrazeneca.com.'},
{ 'key': '1731_CR12',
'unstructured': 'European Medicines Agency. EVUSHELD 150 mg + 150 mg solution for '
'injection: EU summary of product characteristics. 2022. '
'https://www.ema.europa.eu/. Accessed 2 May 2022.'},
{ 'key': '1731_CR13',
'unstructured': 'AstraZeneca Canada Inc. EVUSHELDTM (tixagevimab and cilgavimab '
'injection): Canadian product monograph. 2022. '
'https://covid-vaccine.canada.ca/info/pdf/evusheld-pm-en.pdf. Accessed 11 '
'May 2022'},
{ 'key': '1731_CR14',
'unstructured': 'Department of Health Abu Dhabi. Abu Dhabi receives the first global '
'shipment of the new AstraZeneca “Evusheld” COVID-19 medication [media '
'release]. 20 Dec 2021. https://www.doh.gov.ae/en/news/.'},
{ 'key': '1731_CR15',
'unstructured': 'AstraZeneca. AstraZeneca’s Evusheld™ (tixagevimab and cilgavimab) '
'granted provisional approval for pre-exposure prophylaxis (prevention) '
'of COVID-19 in Australia’s most at-risk [media release]. 25 Feb 2022. '
'https://www.astrazeneca.com.au.'},
{ 'key': '1731_CR16',
'unstructured': 'AstraZeneca. Samsung Biologics and AstraZeneca expand strategic '
'manufacturing partnership to include COVID-19 and cancer therapy [media '
'release]. 13 Dec 2021. http://astrazeneca.com.'},
{ 'key': '1731_CR17',
'unstructured': "Lonza. Lonza announces agreement to manufacture AstraZeneca's COVID-19 "
'long-acting antibody combination [media release]. 30 Oct 2020. '
'http://www.lonza.com.'},
{ 'key': '1731_CR18',
'unstructured': 'Vanderbilt University. Vanderbilt University Medical Center and '
'AstraZeneca join forces to identify potential COVID-19 treatments [media '
'release]. 8 Apr 2020. http://www.vsumc.org.'},
{ 'key': '1731_CR19',
'unstructured': 'AstraZeneca. Researching antibodies to target COVID-19. 2020. '
'https://www.astrazeneca.com/media-centre/articles/2020/researching-antibodies-to-target-covid-19.html#. '
'Accessed 5 May 2022.'},
{ 'issue': '12',
'key': '1731_CR20',
'doi-asserted-by': 'publisher',
'first-page': '6147',
'DOI': '10.1128/AAC.01285-13',
'volume': '57',
'author': 'GJ Robbie',
'year': '2013',
'unstructured': 'Robbie GJ, Criste R, Dall’acqua WF, et al. A novel investigational '
'Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an '
'extended half-life in healthy adults. Antimicrob Agents Chemother. '
'2013;57(12):6147–53.',
'journal-title': 'Antimicrob Agents Chemother'},
{ 'issue': '635',
'key': '1731_CR21',
'doi-asserted-by': 'publisher',
'first-page': 'eabl8124',
'DOI': '10.1126/scitranslmed.abl8124',
'volume': '14',
'author': 'YM Loo',
'year': '2022',
'unstructured': 'Loo YM, McTamney PM, Arends RH, et al. The SARS-CoV-2 monoclonal '
'antibody combination, AZD7442, is protective in nonhuman primates and '
'has an extended half-life in humans. Sci Transl Med. '
'2022;14(635):eabl8124.',
'journal-title': 'Sci Transl Med.'},
{ 'issue': 'Pt 6',
'key': '1731_CR22',
'doi-asserted-by': 'publisher',
'first-page': '700',
'DOI': '10.1107/S0907444908007877',
'volume': '64',
'author': 'V Oganesyan',
'year': '2008',
'unstructured': 'Oganesyan V, Gao C, Shirinian L, et al. Structural characterization of a '
'human Fc fragment engineered for lack of effector functions. Acta '
'Crystallogr D Biol Crystallogr. 2008;64(Pt 6):700–4.',
'journal-title': 'Acta Crystallogr D Biol Crystallogr'},
{ 'issue': '10',
'key': '1731_CR23',
'doi-asserted-by': 'publisher',
'first-page': '1233',
'DOI': '10.1038/s41564-021-00972-2',
'volume': '6',
'author': 'J Dong',
'year': '2021',
'unstructured': 'Dong J, Zost SJ, Greaney AJ, et al. Genetic and structural basis for '
'SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat '
'Microbiol. 2021;6(10):1233–44.',
'journal-title': 'Nat Microbiol'},
{ 'issue': '3',
'key': '1731_CR24',
'doi-asserted-by': 'publisher',
'first-page': '467',
'DOI': '10.1016/j.cell.2021.12.046',
'volume': '185',
'author': 'W Dejnirattisai',
'year': '2022',
'unstructured': 'Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 '
'leads to widespread escape from neutralizing antibody responses. Cell. '
'2022;185(3):467-84 e15.',
'journal-title': 'Cell'},
{ 'issue': '1',
'key': '1731_CR25',
'doi-asserted-by': 'publisher',
'first-page': '4683',
'DOI': '10.1038/s41598-022-08559-5',
'volume': '12',
'author': 'F Touret',
'year': '2022',
'unstructured': 'Touret F, Baronti C, Bouzidi HS, et al. In vitro evaluation of '
'therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate. '
'Sci Rep. 2022;12(1):4683.',
'journal-title': 'Sci Rep'},
{ 'issue': '10321',
'key': '1731_CR26',
'doi-asserted-by': 'publisher',
'first-page': '234',
'DOI': '10.1016/S0140-6736(21)02844-0',
'volume': '399',
'author': 'W Dejnirattisai',
'year': '2022',
'unstructured': 'Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of '
'SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet. '
'2022;399(10321):234–6.',
'journal-title': 'Lancet'},
{ 'issue': '3',
'key': '1731_CR27',
'doi-asserted-by': 'publisher',
'first-page': '490',
'DOI': '10.1038/s41591-021-01678-y',
'volume': '28',
'author': 'LA VanBlargan',
'year': '2022',
'unstructured': 'VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 '
'B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal '
'antibodies. Nat Med. 2022;28(3):490–5.',
'journal-title': 'Nat Med'},
{ 'key': '1731_CR28',
'unstructured': 'US Food and Drug Administration. Open data portal | SARS-CoV-2 variants '
'and therapeutics: therapeutic activity explorer. 2022. '
'https://opendata.ncats.nih.gov/variant/activity. Accessed 6 May 2022.'},
{ 'key': '1731_CR29',
'doi-asserted-by': 'crossref',
'unstructured': 'Case JB, Mackin S, Errico J, et al. Resilience of S309 and AZD7442 '
'monoclonal antibody treatments against infection by SARS-CoV-2 Omicron '
'lineage strains. bioRxiv. 2022(PPR469910):1–33.',
'DOI': '10.1038/s41467-022-31615-7'},
{ 'issue': '3',
'key': '1731_CR30',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.pone.0248348',
'volume': '16',
'author': 'SN Neerukonda',
'year': '2021',
'unstructured': 'Neerukonda SN, Vassell R, Herrup R, et al. Establishment of a '
'well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization '
'assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS '
'ONE. 2021;16(3): e0248348.',
'journal-title': 'PLoS ONE'},
{ 'key': '1731_CR31',
'doi-asserted-by': 'publisher',
'unstructured': 'Driouich J-S, Lingas G, Luciani L, et al. Activity of '
'tixagevimab/cilgavimab against the Omicron variant of SARS-CoV-2 in a '
'hamster model. 2022. https://doi.org/10.21203/rs.3.rs-1399448/v1. '
'Accessed 10 May 2022.',
'DOI': '10.21203/rs.3.rs-1399448/v1'},
{ 'key': '1731_CR32',
'unstructured': 'AstraZeneca. Update on AZD7442 STORM CHASER trial in post-exposure '
'prevention of symptomatic COVID-19 [media release]. 15 June 2021. '
'https://www.astrazeneca.com.'},
{ 'key': '1731_CR33',
'doi-asserted-by': 'publisher',
'unstructured': 'Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of '
'intramuscular administration of tixagevimab-cilgavimab for early '
'outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, '
'double-blind, placebo-controlled trial. Lancet Respir Med. 2022. '
'https://doi.org/10.1016/S2213-2600(22)00180-1.',
'DOI': '10.1016/S2213-2600(22)00180-1'},
{ 'key': '1731_CR34',
'doi-asserted-by': 'publisher',
'DOI': '10.2139/ssrn.4087355',
'author': 'TL Holland',
'year': '2022',
'unstructured': 'Holland TL, Ginde AA, Paredes R, et al. Tixagevimab/cilgavimab for '
'treatment of hospitalised COVID-19 patients: a randomised, double-blind, '
'phase 3 trial. Lancet. 2022. https://doi.org/10.2139/ssrn.4087355.',
'journal-title': 'Lancet'}],
'container-title': 'Drugs',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40265-022-01731-1.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://link.springer.com/article/10.1007/s40265-022-01731-1/fulltext.html',
'content-type': 'text/html',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://link.springer.com/content/pdf/10.1007/s40265-022-01731-1.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 7, 12]],
'date-time': '2022-07-12T21:04:09Z',
'timestamp': 1657659849000},
'score': 1,
'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s40265-022-01731-1'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 6]]},
'references-count': 34,
'journal-issue': {'issue': '9', 'published-print': {'date-parts': [[2022, 6]]}},
'alternative-id': ['1731'],
'URL': 'http://dx.doi.org/10.1007/s40265-022-01731-1',
'relation': {},
'ISSN': ['0012-6667', '1179-1950'],
'subject': [],
'container-title-short': 'Drugs',
'published': {'date-parts': [[2022, 6]]},
'assertion': [ { 'value': '21 June 2022',
'order': 1,
'name': 'first_online',
'label': 'First Online',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}},
{ 'value': 'The preparation of this review was not supported by any external funding.',
'order': 2,
'name': 'Ethics',
'group': {'name': 'EthicsHeading', 'label': 'Funding'}},
{ 'value': 'During the peer review process the manufacturer of the agent under review was '
'offered an opportunity to comment on the article. Changes resulting from any '
'comments received were made by the authors on the basis of scientific '
'completeness and accuracy. Susan J. Keam is a contracted employee of Adis '
'International Ltd/Springer Nature, and declares no relevant conflicts of '
'interest. All authors contributed to the review and are responsible for the '
'article content.',
'order': 3,
'name': 'Ethics',
'group': {'name': 'EthicsHeading', 'label': 'Authorship and Conflict of interest'}},
{ 'value': 'Not applicable.',
'order': 4,
'name': 'Ethics',
'group': { 'name': 'EthicsHeading',
'label': 'Ethics approval, Consent to participate, Consent to publish, '
'Availability of data and material, Code availability'}},
{ 'value': 'This content has been made available to all.',
'name': 'free',
'label': 'Free to read'}]}
